(In Fact, We’ll Guarantee It!)

Dear Reader,

Once in a very rare while, the market hands you a second chance.

And that’s what’s happening now…

…With a medical device company that recently doubled in price for us – and continues to be one of the best money making opportunities I’ve seen in my 13 years of researching up-and-coming companies with breakthrough products.

The company just aced its Phase III trial results, just as we predicted it would. And it’s now awaiting final FDA approval for the go-ahead to market a medical device that could revolutionize the way one of the deadliest types of cancer is detected.

Once that approval comes, we expect this stock to double again within days of the announcement… and keep climbing from there as the company rolls out this innovative (and profitable) device to eager doctors throughout the country.

What does this mean to you?

It’s a rare opportunity to be early in on what can only be described as a potential “legacy stock”. The 100% gains we’re anticipating by September 30th of this year are only the beginning.

As you read through this letter, you’ll learn about the enormous profit potential this company holds – and why we believe this little stock could turn a $10,000 investment into $490,000 over the next five years.

This truly is an opportunity to take back the wealth the market’s stolen from you in recent months… and set you on a clear course to an early and comfortable retirement.

And while no one can say for sure whether the FDA will approve this innovative and life-saving device, I’m more confident than at any other time in the 16 months I’ve been following, researching and recommending this company, that the “green light” is just a few months away.

The company is pretty certain as well.

Based on the huge success from the Phase III (and final) trials, they’ve already started ramping up the manufacturing process for this new cancer detection device and will be ready to ship within weeks of the approval.

Of course you’re likely to already be sitting on a very nice gain when that happens… watching your profits grow day by day as institutional investors jump off the sidelines to snap up the relatively small float of shares available on this potentially explosive stock.

Nothing Can Send Shares Soaring
Like an FDA Approval

The important thing is to get in now – while the price is still trading around $4 a share. Because look what can happen when the kind of “price movement catalyst” we’re expecting takes place:

Cryolife went from $6.75 to over $16 following its FDA clearance to market its heart valve technology…

ATS Medical soared from $1.60 a share to over $3 when it received FDA approval for its mechanical heart valve…

Epix Pharmaceuticals went from 36 cents to $1.66 within two days when the FDA cleared its blood vessel imaging product late last year…

EV3 Inc. better than doubled in the three weeks leading up to FDA approval for it’s balloon catheter products…

Omrix Biopharmaceuticals shot up 173% between the time it’s product gained FDA approval and it was acquired.

Fact is, there are hundreds of examples over the years of innovative little companies producing breakthrough products for the medical industry who have watched their stock prices soar after FDA blessings.

But as I said, the initial market reaction is just one small reason to consider owning shares in this remarkable little company. The real profits could come, should you hold on to some or all of the stock – as this company’s innovative product becomes a mainstay in hospitals and doctors’ offices throughout the country.

There’s simply no time to waste, so here are the details in a nutshell...

The small company I’m writing you about today has developed a revolutionary device that could have a profound impact on the way doctors diagnose and treat melanoma skin cancer.

I’m as close to this situation as anyone in the country, and let me just say – I’ve never seen so much excitement from the medical community over a single innovation as I have with this one.

In fact, doctors I’ve talked to – doctors who have used test versions of this device – say there’s no doubt they’ll buy it and use it once it becomes available.

Why? Because besides being a substantial source of revenue for doctors everywhere, it could forever change the way skin cancer is detected from this day forward.

Rather than “eyeballing” suspicious marks on a patients’ body as a way of detecting melanoma skin cancer, doctors may soon be able to hold this simple hand-held device over suspect areas of the body and know instantly – with 99% accuracy – whether the lesion is cancerous or not.

Currently no such device exists. But this promises to take all the “guess work” out of skin cancer detection forever.

Life-Saving Technology that’s Priceless

Melanoma skin cancer, as you probably know, is deadly in its late stages. It’s estimated that melanoma kills over 8,700 Americans every year, a number that’s rising 6% a year, making it the fastest growing cancer.

But caught early, it’s also one of the most treatable. That’s why doctors check for suspect blemishes in virtually every routine exam.

You’ve probably experienced the skin cancer detection procedure yourself first hand. One of the first things your doctor will do during a routine exam is check your skin for suspicious marks using something called the “ABCDE” method, which is an acronym for the various characteristics of a suspect lesion: Asymmetry, Border irregularity, Color variation, Diameter, and whether the area of concern is “Evolving” over time. If he or she finds anything suspect, a biopsy of the area will be ordered... a procedure, which is not only painful but also time-consuming, stressful and expensive.

But here’s the thing: Studies show that even the best dermatologists miss up to 30% of all melanomas. That’s not only dangerous (and potentially deadly) for the patient, but thousands of doctors have faced expensive malpractice suits because they missed a mark on a patient’s body that later turned out to be cancerous.

This company’s device eliminates the guesswork that can lead to these deadly mistakes.

In Phase III clinical testing, the device accurately identified 125 out of 127 melanomas – a very impressive 98% success rate. Meanwhile, dermatologists using the ABCDE method were only able to identify 70% of the melanomas.

That’s why doctors are very excited about this device. Not only does it allow them to provide much more accurate diagnostic advice to their patients, but it greatly reduces the chances of malpractice suits should they miss something during a routine check up.

Listen to what one professor of dermatology at the University of Alabama in Birmingham said about this amazing little device:

“All I have is my good judgment [to diagnose a lesion as suspicious for melanoma], but if I have a tool that will improve my performance, I think almost everyone will integrate this into their practice.”

A New Revenue Stream for Doctors As Well...

It’s a great revenue stream for them as well. According to the American Journal of Medicine, Americans schedule an estimated 36 million routine exams annually. Doctors using this device will be able to charge a fee – and it likely won’t be long until insurance companies, eager to reduce the cost of unnecessary biopsies and late stage melanoma treatment, will be more than willing to cover the modest costs.

Which brings me full circle to the opportunity before you today – and why this could be a tremendous financial windfall for you in the days ahead.

Right now, as I write you today, the Phase III (and final) trial process is closed, the results have been released and the device passed with flying colors. Any day now, the company will file its application with the FDA for final approval – another event that history tells us could cause a jump in the stock’s price.

Then, within 180 days (because of the life-saving nature of the device, the FDA has granted this project a much coveted “fast track” status), the FDA should make its decision.

If approved, I believe this company’s stock price will jump dramatically – by 100% or more…

$5,000 into $13,000 Virtually Overnight

That means if you were to invest, say, $10,000 in this company today, you could watch your investment jump to over $26,400 practically overnight.

And if you decide to hold your shares and wait for the stock price to reflect the potential profits this device could generate, you could watch your investment grow to more than $130,000 over the coming 12 to 18 months… and $433,600 over the longer term. (I’ll show you how those numbers are possible in a short moment…)

Of course I’d be irresponsible if I didn’t tell you: There’s a chance the FDA will not approve this company’s device, in which case the stock price will likely fall.

But as I mentioned before, I’ve been following this stock on a daily basis for over a year now – ever since my research uncovered the tremendous success this device was enjoying in early testing.

In that time I’ve found nothing but strong evidence that this device is likely to gain the seal of approval from the FDA – and could be on the market and in the hands of very eager doctors very soon.

Why Are Company Insiders Loading Up?

Here are the most compelling reasons I believe we’ll see an approval very soon:

• First and foremost, the Phase III trials show the device works. The company’s “primary endpoint” for the study was a 95% success rate, yet the device achieved a 98% success rate, accurately identifying 125 out of 127 melanomas. Based on the 70% accuracy rate quoted among dermatologists in the study, only 89 of those melanomas would have been identified using the current ABCDE method.
  
  
• It’s safe. Because this is a medical device and not an ingestible, there are no safety concerns what so ever. Fact is, most products fail to get FDA approval solely because of safety reasons and adverse side effects.
  
  
• A tremendous amount of insider buying by executives and directors. On the heels of Phase II results and leading up to the Phase III data results release, company insiders scooped up shares on 25 occasions, adding more than 199,000 shares to their already substantial positions – all at market prices and paid for out of the insiders’ personal accounts (among them, one legendary “start-up” maven with a 48-year history of snapping up shares of little-known companies with undiscovered potential and growing them into billion-dollar concerns).
  
  
• The company recently hired a VP of Commercialization… who’s in the process of putting together an aggressive commercialization plan exclusively for this product. With no other products ready to market, it’s unlikely this company would have made the investment if they weren’t confident they’d soon have a product to market.
  
  
• The company’s begun the early manufacturing process. Confident the device will gain approval, the company has already started the sub-assembly process, so it can hit the ground running once approval is granted, and get the device to the growing list of doctors who want it once it’s available.
  
  
• This is a diagnostic device – with “fast-track” designation. The FDA is much more stringent when it comes to approving ingestible drugs, than it is with diagnostic devices such as this one, since there are no adverse side effects for the patient. Plus, because of the potential life-saving impact this device can have on so many people – and given its “critical need” status – it was able to gain “fast-track” designation, which speeds up the approval process.

And Then There are the “Tell Tale” Signs...

But here’s the thing I want you to know. I have made a very successful living over the past 13 years researching small companies working on important innovations like this one – both as a Senior Analyst at Wall Street’s most contrarian research firm, hired by the biggest investment and hedge funds in the world… and most recently as the Research Director for my own institutional-style advisory service called Access.

And during that much time, you start to learn the little “tell tale” signs that a company’s confident in its innovations. You see it in the upbeat nature of its communications – and how willing they are to answer the hard questions you ask them.

You see it in the way the company goes about its business, looking to the long-term – even if today’s tough decisions could impact the share prices in the short-term.

You see it in the way company executives, directors and even salaried employees quietly and consistently buy up the company stock. Even when share prices were higher than they are today, company insiders were diligently buying shares at market prices, with their own money… perhaps the surest sign of confidence in the product they’ve spent years developing.

And perhaps most telling is the passion in their voice when they talk about the product. I’ve spoken with many company executives over the last16 months – and I can honestly tell you that these people (the CEO is also an MD) are more interested in the life-saving aspect of this cancer detection device than they are about getting rich from it.

It’s for all these tangible and intangible reasons that I recommended this little company to subscribers of my Access research service several months ago.

If you’re not familiar with it, Access is a premier institutional-style research service geared to everyday individuals looking for the kind of information and research typically reserved for hedge fund and investment firm managers.

I’m talking small-cap and up-start companies that are in what we like to call “the gathering period” – where influential investors, insiders and sector specialists are accumulating substantial positions ahead of breakthrough news and/or product announcements.

Here’s a quick example.

102% to $2,650% Gains in Just 5 Months

One company we’ve uncovered had a promising drug in Phase III trials that treated a medical condition called Phenylketonuria (PKU) – a disorder characterized by increased amounts of the amino acid phenylalanine in the bloodstream of infants that can lead to mental disabilities.

But my research – and my contacts in the medical field – confirmed this was an important development… the first and only of its kind. What’s more, no other drug company had anything similar in the pipeline, which meant when and if the drug gained FDA approval, there would be no competition whatsoever.

More research confirmed the drug was being “fast-tracked” – which means the FDA will speed up the approval process because of the urgent medical need. It was just a matter of months before there was a very high likelihood that the drug would gain approval.

So I put out a recommendation to buy the company at $18.35 a share. A few weeks later, news of the drug hit Wall Street. The stock soared, hitting our target price of $40 within five months.

And Our Readers Responded…

Those who followed the recommendation had an opportunity to walk away with solid money-doubling gains in just five months – like John S., from Houston, TX:

“Great call on this stock! Without your recommendation I never would have even heard of this company. I am up 101.75% and will sell half of my position on Monday. Please continue to bring these types of picks! I realize that there is always uncertainty around the FDA approval process, but you nailed this one. Again, great job!”

Even though Access in not an options service, members are free to buy options on any play, especially when my research suggests the stock could move quickly – like this little drug researcher did once Phase III trials results were announced.

Needless to say, those folks who did, made even more profits:

“Last Friday, I sold all 10 contracts for $11 each!! Turning my $400 investment into an $11,000 return – a gain of $10.60 per contract!! (Not including the $40 'round trip' for brokerage). Not sure what percentage gain that is but I sure am going to have a great Christmas!”
– Jason R., Australia

“Great call! I bought the Jan 09 $17.50 calls at $5.30 in July 07 and sold them today at $19.50. Sweet! Keep up the good work.”
– Joe M., Easley, SC

“I decided to go the options route and purchased January 08 calls at $2.10. Sold 40 percent in October for a 57.1% locked in gain. Today I sold the balance for an additional 447.6% gain. Total gain: About 505%.”
– Don G., Chester, PA

Another 65% Gain

And in one of the toughest markets in history, we locked in a 65% gain by closing out a partial position in another high-flying under-the-radar company. And we fully expect to book even more gains on our remaining position in the stock once the company finalizes a very “hush-hush” 9-figure U.S. government deal before the end of October 2009.

And that’s why we’re so excited about what I believe could be an enormous money-making opportunity with the little company that’s developed this breakthrough hand-held skin cancer detection device.

This is a very real opportunity to be a part of an important medical breakthrough at what can only be described as a ground-floor “buy in” price.

And should the positive phase III results just released lead to FDA approval (as we expect it will… by September 30th of this year) we fully expect the profits to start rolling in.

Three Stages of Profits

The first jump should come on the news. Right now, institutional investors are waiting until there’s something concrete to grab onto – like rock-solid proof that this device will make it to market. There’s no question that an FDA approval will do the trick, since the company’s ramping up production and will be ready to roll out almost immediately. Once investors get that assurance, money is likely to fly into this stock quickly, driving the price 50%, 100% even 300% higher in a matter of days.

Then, when investors and analysts take a closer look at the business, they’ll learn what we already know:

• The company has already streamlined its manufacturing process for this device, meaning units will be ready to ship with little or no backlog when sales start rolling in…
  
  
• The product is easily affordable by any doctor. The average cost for this device is a mere $5,000 – chicken feed when compared to the tens, even hundreds of thousands of dollars doctors and hospitals are used to paying for most diagnostic equipment. (And it’s a big reason why the company already has a long list of doctors who want the machine just as soon as it can ship).
  
  
• Sales of the device itself are just a small portion of the anticipated revenues. The bulk of the profits will come from proprietary memory cards required to store diagnostic results and history on a patient-by-patient basis. For each patient, a memory card is required. Based on the company’s research, the average doctor’s practice could generate an extra $130,000 revenue per year through routine use of this device.
  
  
• If this company places one machine in just 10% of the country’s 11,000 dermatology practices alone – and those clinics use the machine just 60 times a week – revenues could surpass $240 million.
  
  
• When word catches on about its effectiveness in detecting cancer within a few minutes, it’s very possible this device could be a mainstay fixture in clinics, doctors’ offices and hospitals. If the device gets into even a third of all dermatologists’ offices alone, revenues could eclipse $825 million…

Once medical sector analysts on Wall Street begin to understand these things about this little company… that’s when the word gets out and the real buying begins.

They’ll quickly discover that based on very conservative sales of $240 million – and profit margins of even half of the projected 15% – this little company could soon be earning $1.20 a share or more. Using average industry price-to-earnings that translates to $59 a share – a long way from today’s price of around $4.

And that’s just the short-term potential...

$4 to $196 A Share? It’s All-Together Possible.

That’s when things really get fun. Based on the same, very conservative, 7.5% profit margin… and very conservative PE ratios… we’re looking at a share price for this company that could very well eclipse the $196 mark…

In other words, if you were to buy 2,500 of this company’s shares today for somewhere in the $10,000 range – you could wake up in a few years’ time and find your 2,500 shares worth $433,000.

Needless to say, I want you to get in on this opportunity.

But more importantly, I want you to see the kind of extraordinary research we do here... and how we're able to unearth the kind of companies that can have a profound impact on your immediate wealth.

As I’ve mentioned, Access is a serious research service aimed at individuals who want to see the kind of “private” ground floor opportunities typically reserved for institutional investors and insiders.

The research reports you’ll see as an Access member are identical to the ones I prepared for top hedge funds during my days as a professional Wall Street researcher – reports institutional investors routinely paid hundreds of thousands of dollars to see.

But that’s not all. In addition to my detailed research reports, every Access member is invited to take part in conference calls whenever a new recommendation is issued. It’s here we invite an impartial industry expert to join us in asking the difficult questions of company executives so you can get a sense beyond the hard research whether this is a company you want to be part of.

And, of course, there’s the relentless follow up I’m well known for. Even after the recommendation goes out, I’m on the phone almost daily – to the company, industry experts, and my insider contacts – following the progress and making sure there’s nothing to put your anticipated gains in jeopardy.

Needless to say, research of this caliber doesn’t come cheap… which is why Access members are happy to pay the $2,750 a one-year membership costs. Members like Burt K. from New Jersey, in fact, who wrote me just the other day:

“Just wanted to let you know what a great job you did as the host of our telephone conference recently. I look forward to receiving additional Access reports in the future. Your research is top notch and well worth the price.”

Still, I know you’ve yet to see our research first hand. And I can fully understand how you might have some reservations paying that kind of money in this difficult market without “test driving” the advisory service first.

So here's what I propose.

Right off the bat, for a very limited time, I’d like to take $1,000 off the price I normally charge for my research. So instead of $2,750 – your price is just $1,750.

Believe me – we don’t do this often. Once this limited time offer expires, the price of membership could go back up to the retail membership price of $6,000… and may stay there for some time.

But during these times, I want to make it even easier for you.

Rather than paying that amount up front, I want to give you a quarterly payment option, where you pay just $450, billed to your credit card every three months.

And just so you know, that entitles you to receive everything the research subscribers who have paid the full $2,750 got – including regular e-mails alerts, all new recommendations, special research reports and, of course, your participation in our regular new recommendation live conference calls.

A Shot at Profits – or You Don’t Pay

Because I’m so confident that the little company I’ve been telling you about will gain FDA approval – and the stock will at least double when it happens – I want to offer you the following guarantee:

Sign up for your subscription to Access today. You can choose the quarterly $450 option or pay the discounted $1,750 price in full – it’s your choice…

Then, if for any reason this little company’s cancer detection device is not approved by the FDA and the stock does not at least double in price between now and a week following the FDA announcement – you’re entitled to have every dime you’ve paid towards your subscription returned to you, no questions asked.

In other words, if the company I’m writing you about today isn’t trading at at least $8 per share between now and a full seven (7) days following the FDA’s announcement – then you can request a full refund of any amount you’ve paid us towards your subscription.

Frankly, I have no problem offering you this guarantee.

I firmly believe the little medical company I’ve been telling you about will not only double on the FDA news – but could produce hundreds of thousands of dollars in longer term profits as the company’s innovative little device gains acceptance… first in the United States, and later around the world.

Like I mentioned before, I believe this is truly one of those “legacy stocks” – the kind you can buy cheap and watch appreciate quarter after quarter as the sales numbers and company profits start rolling in.

And there’s nothing I’d like better than to see you share in those gains.

Of course, your membership also entitles you to details and reports on five more very exciting (and also timely) situations currently in the Access model portfolio.

In fact, these companies continue to perform beautifully, even in this difficult market... despite the fact that the catalysts we’re expecting to drive these shares higher are still a few weeks away.

And like the little diagnostics company I’ve been telling you about, insiders are very active in a number of them as they line-up their stakes in this, “gathering” period for these stocks.

Here’s a snapshot for you.

164% potential gains on this non-controversial stem cell play…

A non-embryonic stem cell company with existing products in the marketplace. Physicians who use their products are already expanding its use beyond what it’s been approved for – opening the door to dozens of new uses. Many clinical trials are currently underway to gain approval for expanded use. If those are strong, investors will recognize this therapy is for real. Projected gains: 164%

Potential take-over target with 55% potential gains...

A cash-rich biotech company with two popular drugs on the market and a strong candidate in the pipeline. Management has an excellent track record of making solid acquisitions and Wall Street’s just now starting to warm up to this story. We like this company because it’s a strong candidate to be acquired by a big pharmaceutical in need of revenue generating drugs and a strong pipeline. Potential near-term gains: 55%

Potential 100% gains by the end of the year…

A growing pharmaceutical company with a deep and impressive pipeline of new drug therapies that should get a huge price bump once it signs a pending development deal for its leading drug candidate.

$100 Million to fight bio-terror. Potential gains of 165%...

A biotechnology company that’s expected to land a $100 million contract from the U.S. government for a product that combats bio-terror and viruses. We’ve already booked 65% gains on this little stock when we closed out half of our position at the end of January. Plus, the stock’s been climbing nicely higher ever since, moving well towards our $9.50 target.

369% potential gains on this medical device innovator...

A medical device maker that’s another strong acquisition candidate. It’s developed a number of innovative new products – among them a product for the female market with the potential for $500 million in new sales if it captures the same 5% of the market it currently has for its men’s version of the product. Potential gains: 369%

Of course you’ll get full reports with all the details on each of these companies once you sign up for your Access membership.

Any one of the six companies you’ll learn about could have a profound impact on your wealth. They’re companies that are truly in the early “gathering” stages, each with important events on the near-term horizon that could drive these stocks much higher, very quickly.

The medical, government and security related products and innovations that each of these companies are involved with are virtually recession proof – so they’re far less vulnerable to the whims and mood of a nervous market.

What’s more, they fit the Access selection criteria perfectly: Little known companies, flying well under-the-radar, with highly promising, groundbreaking and innovative products just months away from market.

Of course, today I want to focus on the cancer detection device because that company’s stock-boosting catalyst – the FDA approval that will allow the company to begin marketing it’s exciting and life-saving cancer detection device to doctors around the country.

I honestly believe this is the best investment opportunity on the market today – and your very best opportunity to be part of one of those 40-to-1 returns you typically read about after the opportunity is long gone.

Winners like this have a history of happening – especially in the highly flying medical and biopharmaceutical sectors. Just look at all the huge successes that have come before this one:

• Amgen went from $1 in the early 1990s to a $75 stock over the course of a decade…
  
  
• Biogen Idec rocketed from 42 cents to more than $46 over a five-year stretch…
  
  
• Celgene Corporation went from a 50-cent stock to $18.50 in less than two years – on it’s way to a high of over $75. Anyone who knew what Celgene was up to early on could have watched a $5,000 investment grow into a whopping $750,000!
  
  
• Genentech grew from $1.80 per share to a high of over $90 based on its biotech innovations…
  
  
• Gilead Sciences went from 48 cents a share to over $50… turning an “early-in” investor’s $5,000 stake into over $520,000.
  
  
• Onyx Pharmaceuticals shot from $4 a share (the price our little medical company trades at today) to over $58 a share in less than 2 years…

All great examples of what biotech companies with innovative products can do when one early success helps to spawn a thriving pipeline of quality, profitable products.

The Best Research You’ll Find, On or Off, Wall Street

I’m tremendously proud of the research my team and I do here at Access.

Institutional money managers tell me the research I publish is as good – or better – than any they’ve seen anywhere. Even from some of the most prestigious firms on Wall Street. (In fact, I’ve been asked to consult for hedge funds, but I’ve politely decline. When I started Access, my goal was to give typical individuals like you access to the kind of research the big guys are privy to, so you can have the same “edge” on the market that they do…)

That’s why we spend a fortune every year traveling to companies’ headquarters, wining and dining industry contacts, trying to squeeze out by any legal means close-to-the-bone information that will lead us to hidden opportunities with enormous potential.

At the same time, I know this is a very difficult time for most investors, given how tight money is these days – and how crazily unpredictable the broad market is right now. That’s why I’m more than happy to extend to you this unprecedented “profit-or-else” guarantee – and an opportunity to experience the gains I’m promising I’ll show you, without obligation.

I’m so convinced that this opportunity could reward you so profoundly that I want to “put my money where my mouth is” as it were.

I want to give you every reason to get in now and see gains from the little company I believe is poised to double (or better). If I’m right, my hope is you’ll see the value of this research and stay on with us as an Access member for many years to come... and benefit from all the research we do from this day forward.

It’s really as simple as that.

How This Limited Time Offer Works

So here’s how this limited time offer works once more:

To gain instant access to all our current research, as well as the specific recommendation I'll provide on this little medical company, for your Access membership at the discounted price of $1,750… or choose the quarterly payment option for $450 billed to your credit card every three months.

Through this offer only, you can see all of our research right up until the FDA’s announcement risk free. And if the little company I’ve been telling you about isn’t trading a $8 per share anytime between now and a week following the news of the FDA approval, you can request and receive a full refund of any amount you’ve paid towards your subscription.

Time is of the Utmost Essence

The important thing right now is to get yourself signed up for your “risk-free” membership now – so we can get the special report on the medical device company in your hands immediately... and you can buy the stock now, before it takes off once rumors of an FDA approval begin to circulate.

But I urge you to hurry.

We’ve been watching this company for over a year now. Many Access members have held it for several months... in anticipation of this event.

I wish I could tell you a precise date when the approval will come through. But I can’t. All I do know is that the FDA typically issues fast-track approvals within 180 days of the application being submitted… and very often the stock moves higher in anticipation of the news.

. If you'd rather activate your membership by phone, please call our VIP Services team at 888-570-9830 or 410-454-0498 and offer Priority Code:

And get everything you need to take action – and participate in the potential gains this little company is poised to generate in the weeks and months to come.

Sincerely,

Marc Lichtenfeld
Director of Research
Access Research Group
March 25, 2009

P.S. Remember, our little cancer detection device company isn’t the only one in the Access portfolio expecting news or announcements that could send the stock price substantially higher. All six of the companies you’ll learn about are there because of imminent near-term “catalysts” (announcements, pending deals, takeover situations) that could bring significant overnight profits.

In fact, a quick calculation tells me we could be looking at 496% gains in the near-term from these companies… enough to turn a $5,000 investment in each into $208,900. That’s why I urge you to take advantage of this very special offer where you can get all the details right away under the terms of this risk-free deal – and then take six months to decide if you want to keep seeing our research.

P.P.S. Of course, we can’t extend this $1,000 discount forever... which is why we’ll be putting the price back up at midnight April 14th. But 36% savings aside, it’s even more important that you own a piece of this exciting little company when the stock price doubles (or better) once the FDA approval comes down.